Tazverik
Chemical Name | tazemetostat |
Dosage Form | Tablet (oral; 200 mg) |
Drug Class | Inhibitors |
System | Musculoskeletal, Skin |
Company | Epizyme |
Approval Year | 2020 |
Indication
- For the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection